<DOC>
	<DOCNO>NCT02226991</DOCNO>
	<brief_summary>Study investigate effect steady-state Efavirenz ( 600 mg QD ) steady-state pharmacokinetics Tipranavir ( 500 mg BID ) coadministered Ritonavir ( 200 mg BID )</brief_summary>
	<brief_title>Effects Steady-state Efavirenz 600 mg QD ( Sustiva® ) Tipranavir Concentration Steady-state Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>1 . Male female subject 18 60 year age inclusive 2 . A Body Mass Index ( BMI ) 18 29.9 kg/m2 3 . Signed informed consent prior trial participation 4 . Ability swallow multiple large capsule without difficulty 5 . Acceptable laboratory value indicate adequate baseline organ function screen visit Laboratory value consider acceptable severity parameter ≤Grade 1 , base Division AIDS ( DAIDS ) /AIDS Clinical Trials Group ( ACTG ) Grading Scale All abnormal laboratory value &gt; Grade 1 subject approval BI trial clinical monitor 6 . Acceptable medical history , physical examination , 12lead ECG screen 7 . Willingness abstain follow start 2 week prior administration study medication end study : Grapefruit grapefruit juice , red wine , Seville oranges , St. John 's Wort , Milk Thistle 8 . Willingness abstain alcohol start 3 day prior administration study medication end study 9 . Willingness abstain follow start 3 day prior pharmacokinetic ( PK ) sampling : Garlic supplement methylxanthine contain food drink ( include coffee , tea , cola , energy drink , chocolate , etc . ) , apples apple juice 10 . Willingness abstain overthecounter herbal medication duration study 11 . Must nonsmoker 12 . Willingness abstain vigorous physical exercise intensive PK day ; Days 10 24 13 . Reasonable probability completion study 1 . Female subject reproductive potential : Have positive serum pregnancy test Have use barrier method contraception least 3 month prior participation study Are willing use reliable method barrier contraception ( diaphragm spermicidal cream/jelly condoms spermicidal foam ) , 60 day completion/termination trial Are breastfeed . 2 . Use pharmacological contraceptive ( include oral , patch injectable contraceptive ) within 1 month prior Day 1 duration study . Due long halflife , subject use DepoProvera® within six month prior Day 1 exclude participation study 3 . Use hormone replacement therapy within 1 month prior Day 1 anytime study 4 . Participation another trial investigational medicine within 2 month prior Day 1 study 5 . Use medication list Appendix 10.5 within 30 day prior Day 1 study 6 . Administration antibiotic within 15 day prior Day 1 anytime study 7 . History acute illness within 60 day prior Day 1 Subjects exclude acute illness occur 60 day prior Day 1 , opinion investigator , subject qualify healthy volunteer 8 . Have serological evidence hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) 9 . Have serological evidence exposure HIV 10 . Alcohol substance abuse within 1 year prior screen study 11 . Blood plasma donation within 30 day prior Day 1 study 12 . Subjects history illness allergy , opinion investigator , might confound result study pose additional risk administer TPV , RTV EFV subject 13 . History psychiatric disorder require pharmacological psychological treatment 14 . Subjects take ( within 7 day prior Day 1 ) overthecounter prescription medication , opinion investigator consultation sponsor 's clinical monitor , might interfere absorption , distribution , metabolism study medication 15 . Known hypersensitivity sulphonamide class drug 16 . Known hypersensitivity TPV , RTV , EFV antiretroviral drug ( market experimental use part clinical research study ) 17 . Known elevate liver enzyme past trial compound 18 . Inability adhere protocol 19 . Cautions warning RTV EFV package insert , opinion investigator , constitute ground subject exclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>